EOLS Q4 2020 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena

EOLSEvolus, Inc.

$353M

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$21M+5.8% YoY

Gross Profit

$13M64.6% margin

Operating Income

-$108M-525.0% margin

Net Income

-$111M-538.0% margin

EPS (Diluted)

$-3.28

QoQ Revenue Growth

+16.5%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$209M

Total Liabilities

$282M

Stockholders' Equity

-$73M

Cash & Equivalents

$103M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$19M	+5.8%
Gross Profit	$13M	$14M	-7.3%
Operating Income	-$108M	-$16M	-560.3%
Net Income	-$111M	-$15M	-663.0%

Revenue Segments

Product

$21M100%